BioPharma Dive 28. Apr. 2026 FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
BioPharma Dive 28. Apr. 2026 Coultreon banks $125M to support testing of former Galapagos immune drug
BioPharma Dive 28. Apr. 2026 Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
BioPharma Dive 24. Apr. 2026 Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
BioPharma Dive 23. Apr. 2026 Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
BioPharma Dive 20. Apr. 2026 Nektar surges again as alopecia drug shows new promise in extension study
BioPharma Dive 20. Apr. 2026 AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
BioPharma Dive 20. Apr. 2026 [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services